This company has been marked as potentially delisted and may not be actively trading. Presbia (LENS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LENS vs. BVS, CATX, INFU, NSPR, CTCX, HSAQ, GBS, RVP, PETV, and BTCYShould you be buying Presbia stock or one of its competitors? The main competitors of Presbia include Bioventus (BVS), Perspective Therapeutics (CATX), InfuSystem (INFU), InspireMD (NSPR), Carmell (CTCX), Health Sciences Acquisitions Co. 2 (HSAQ), GBS (GBS), Retractable Technologies (RVP), PetVivo (PETV), and Biotricity (BTCY). These companies are all part of the "medical" sector. Presbia vs. Its Competitors Bioventus Perspective Therapeutics InfuSystem InspireMD Carmell Health Sciences Acquisitions Co. 2 GBS Retractable Technologies PetVivo Biotricity Bioventus (NYSE:BVS) and Presbia (NASDAQ:LENS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk. Is BVS or LENS more profitable? Bioventus has a net margin of -7.11% compared to Presbia's net margin of -36,604.35%. Bioventus' return on equity of 15.61% beat Presbia's return on equity.Company Net Margins Return on Equity Return on Assets Bioventus-7.11% 15.61% 4.01% Presbia -36,604.35%-414.02%-195.56% Do analysts rate BVS or LENS? Bioventus currently has a consensus price target of $13.75, suggesting a potential upside of 90.18%. Given Bioventus' stronger consensus rating and higher probable upside, analysts clearly believe Bioventus is more favorable than Presbia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventus 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Presbia 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer BVS or LENS? In the previous week, Bioventus had 2 more articles in the media than Presbia. MarketBeat recorded 2 mentions for Bioventus and 0 mentions for Presbia. Bioventus' average media sentiment score of 1.74 beat Presbia's score of 0.00 indicating that Bioventus is being referred to more favorably in the media. Company Overall Sentiment Bioventus Very Positive Presbia Neutral Which has stronger valuation & earnings, BVS or LENS? Presbia has lower revenue, but higher earnings than Bioventus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioventus$564.14M1.06-$156.23MN/AN/APresbia$20K27,450.41-$8.41MN/AN/A Do institutionals and insiders hold more shares of BVS or LENS? 62.9% of Bioventus shares are held by institutional investors. Comparatively, 16.4% of Presbia shares are held by institutional investors. 33.0% of Bioventus shares are held by company insiders. Comparatively, 74.2% of Presbia shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, BVS or LENS? Bioventus has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Presbia has a beta of 2.57, meaning that its stock price is 157% more volatile than the S&P 500. SummaryBioventus beats Presbia on 10 of the 14 factors compared between the two stocks. Get Presbia News Delivered to You Automatically Sign up to receive the latest news and ratings for LENS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENS vs. The Competition Export to ExcelMetricPresbiaSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$549.01M$80.18M$5.84B$10.14BDividend YieldN/AN/A5.68%4.60%P/E RatioN/A11.4075.4125.98Price / Sales27,450.4180.37515.81181.13Price / CashN/A18.4137.5660.44Price / Book354.0410.9312.156.29Net Income-$8.41M-$26.48M$3.29B$271.07M Presbia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENSPresbiaN/A$31.86-0.1%N/AN/A$549.01M$20K0.0024BVSBioventus3.3113 of 5 stars$7.27+0.8%$13.75+89.1%-35.3%$601.08M$564.14M-11.921,200Positive NewsCATXPerspective Therapeutics1.8305 of 5 stars$3.37-1.7%$12.56+272.6%-76.7%$250.27MN/A0.0070Positive NewsINFUInfuSystem3.3603 of 5 stars$10.42+1.6%$12.50+20.0%+53.9%$209.57M$139.89M173.70410Positive NewsNSPRInspireMD3.6499 of 5 stars$2.46+2.5%$4.50+82.9%-12.5%$102.63M$7.07M-3.2850News CoveragePositive NewsShort Interest ↓CTCXCarmellN/A$2.43-4.7%N/A+307.7%$50.80M$32.84K0.0014HSAQHealth Sciences Acquisitions Co. 2N/A$2.73-0.7%N/A-55.5%$30.61MN/A0.004GBSGBSN/A$1.65+6.1%N/A-10.5%$24.49MN/A-2.947News CoverageRVPRetractable Technologies1.2249 of 5 stars$0.81+1.6%N/A-9.7%$23.83M$38.16M-1.50240Short Interest ↑PETVPetVivoN/A$0.85+3.2%N/A+50.8%$22.99M$1.05M-1.8920News CoverageBTCYBiotricityN/A$0.61-14.1%N/A+86.4%$17.69M$12.06M-0.5640Gap Down Related Companies and Tools Related Companies BVS Competitors CATX Competitors INFU Competitors NSPR Competitors CTCX Competitors HSAQ Competitors GBS Competitors RVP Competitors PETV Competitors BTCY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENS) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of mi...Porter & Company | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Presbia PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Presbia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LENS Stock Alerts